The promise of induced pluripotent stem cells in research and therapy
By Daisy A. Robinton, G. Daley. Nature, 2012
1,130 citations recorded by the source corpus.
The field of stem-cell biology has been catapulted forward by the startling development of reprogramming technology. The ability to restore pluripotency to somatic cells through the ectopic co-expression of reprogramming factors has created powerful new opportunities for modelling human diseases and offers hope for personalized regenerative cell therapies. While the field is racing ahead, some researchers are pausing to evaluate whether induced pluripotent stem cells are indeed the true equivalents of embryonic stem cells and whether subtle differences between these types of cell might affect their research applications and therapeutic potential.
Subfields: Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/548a4690028e058c4876ed9f08639cfd3b594acc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Pioneer Transcription Factors Target Partial DNA Motifs on Nucleosomes to Initiate Reprogramming (2015, positive): “Generating induced pluripotent stem (iPS) cells, using the OSKM factors, has proved to be highly valuable for research, with great potential for regenerative medicine (Robinton and Daley, 2012).”
- Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip (2016, positive): “The hiPSCs represent a versatile cell source for ob taining a variety of mature cell types thanks to recent advancements on the stem cell technology [15, 16, 79, 80].”